NASDAQ:NCNA
NuCana plc Stock News
$3.52
+0 (+0%)
At Close: May 24, 2024
Why NuCana Shares Are Rising Today?
01:52pm, Monday, 11'th Jul 2022
Regional Court of Dusseldorf has ruled in favor of NuCana plc (NASDAQ: NCNA), stating that Gilead Sciences Ireland UC and Gilead Sciences GmbH infringed NuCana's composition of matter claims in Eu
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
08:35am, Tuesday, 05'th Jul 2022 Benzinga
Gainers
Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64.
Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.
Fast Radius, Inc. (NASDAQ: FSRD) jumped 41.2
NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress
11:00am, Friday, 10'th Jun 2022 GlobeNewswire Inc.
NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia
NuCana Announces Receipt of NASDAQ Notice
08:01pm, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LL
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
03:09pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
23 Stocks That Have Sold Off Hard Since The Russia-Ukraine War Began
04:25pm, Friday, 11'th Mar 2022 Benzinga
The S&P 500 is having a rough start to 2022, down 11.27% year to date. Since Russia invaded Ukraine on Feb. 24, the S&P 500 has fallen an additional 0.78%.
Following are lists of sectors via Fidelity
NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022
09:35pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro
NuCana plc (NASDAQ: NCNA) Drops -15.35 Percent In Recent Session, Why Are You Interested?
04:00pm, Tuesday, 08'th Mar 2022 Stocks Register
The trading price of NuCana plc (NASDAQ:NCNA) closed lower on Monday, March 07, closing at $0.81, -15.35% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7789 and … NuCana plc (NASDAQ: NCNA) Drops -15.35 Percent In Recent Session, Why Are You Interested? Read More »
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
03:02pm, Sunday, 06'th Mar 2022 Benzinga
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB ) retreated in four out of five sessions of the week. Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off. NuCana plc. (NASDAQ: NCNA ) was among the worst decliners of the week, with the stock reacting to the stalling of the company''s Phase 3 biliary tract cancer study. SAB Biotherapeutics, Inc. (NASDAQ: SABS ) shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company''s SAB-185 in COVID-19 patients. Celayad Oncology SA (NASDAQ: CYAD ) shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study. FDA decisions scheduled for the week were mixed, with Amryt Pharma plc (NASDAQ: AMYT ) and Gilead Sciences, Inc. (NASDAQ: GILD ) failing to get their investigational drugs across the finish line.
Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)
03:00pm, Friday, 04'th Mar 2022 Zacks Investment Research
NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
03:03pm, Thursday, 03'rd Mar 2022 Benzinga
Upgrades
For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago q
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
12:46pm, Thursday, 03'rd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis
NuCana plc (NASDAQ: NCNA) s
Why Did NuCana Stop Phase 3 Biliary Tract Cancer Trial?
11:13am, Thursday, 03'rd Mar 2022 Benzinga
NuCana plc (NASDAQ: NCNA ) will discontinue its NuTide:121 study following a pre-planned futility analysis by the study''s Independent Data Monitoring Committee (IDMC). The NuTide:121 Phase 3 trial assessed Acelarin plus Cisplatin in patients with previously untreated advanced biliary tract cancer. Although a higher objective response rate was observed in the Acelarin plus cisplatin arm, this
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
09:01pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis
NuCana to Participate in Two Upcoming Investor Conferences
09:01pm, Monday, 28'th Feb 2022 GlobeNewswire Inc.
EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will parti